Conference Coverage

What’s new with adalimumab? Plenty


 

REPORTING FROM SDEF HAWAII DERMATOLOGY SEMINAR

Adalimumab citrate free

Not only does this new iteration of adalimumab do away with citrate as a buffer because it can cause pain and burning, it also utilizes a thinner 29-gauge needle rather than the standard 27-gauge. And the needle cover isn’t made with natural rubber latex. Also, both the pen and prefilled syringe contain half the volume of liquid, compared with the classic version of the biologic, so it’s 40 mg of drug in 0.4 mL rather than in 0.8 mL.

The packaging of adalimumab citrate free is different. It comes in a blue box to distinguish the product from the classic version.

Dr. Duffin reported receiving research grants from and serving as a consultant to AbbVie, which markets adalimumab, as well as close to a dozen other pharmaceutical companies.

The SDEF/Global Academy for Medical Education and this news organization are owned by the same parent company.

Pages

Recommended Reading

Over one-third of psoriasis patients have PsA
MDedge Rheumatology
Weight loss cuts risk of psoriatic arthritis
MDedge Rheumatology
Algorithm proposes approach for managing TNF inhibitor–induced psoriasis
MDedge Rheumatology
CONDOR trial: Most psoriasis patients can be downshifted to reduced-dose biologics
MDedge Rheumatology
Longterm maintenance of PASI 75 responses observed with tildrakizumab
MDedge Rheumatology
Brodalumab raced past ustekinumab to PASI 100
MDedge Rheumatology
Comorbidities may cut effectiveness of psoriasis biologics
MDedge Rheumatology
Guselkumab tops secukinumab over 48 weeks for plaque psoriasis
MDedge Rheumatology
Different disease features found with family history of psoriasis versus PsA
MDedge Rheumatology
Biologics curb coronary artery plaques in severe psoriasis
MDedge Rheumatology